Clinical Trials on Urological Malignancies

Total 18608 results

Novartis Pharmaceuticals

Completed

Phase I Study of PDR001 in Patients With Advanced Malignancies.

Advanced Malignancies

Japan
Regeneron Pharmaceuticals

Withdrawn

Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study

Advanced Malignancies

United States
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Iatrogenic Effects of Treatment for Childhood Cancer Constitution of a Biological Samples Bank (BIO-F)

Paediatric Malignancies

France
Hillel Yaffe Medical Center

Unknown

The Development of an In-vitro System to Identify Gynecologic Cancer Cells During Surgical Procedures

Gynecological Malignancies

Israel
Mirati Therapeutics Inc.

Completed

Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies

Advanced Malignancies

United States
University of Southern California

Terminated

Oral NRX 194204 in Patients With Refractory Malignancies

Refractory Malignancies

United States
Millennium Pharmaceuticals, Inc.

Terminated

A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies

Advanced Malignancies

Spain
Human Genome Sciences Inc.

Terminated

A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Lymphoid Malignancies

United States, United Kingdom
University Hospital, Clermont-Ferrand
Amgen

Unknown

Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5) (MEG-5)

Solid Malignancies

France
Academisch Medisch Centrum - Universiteit van Amsterdam...

Unknown

Everolimus and Capecitabine in Patients With Advanced Malignancy (m-TOR)

Advanced Malignancies

Netherlands
Novartis Pharmaceuticals

Completed

Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies

Advanced Malignancies

United States
Metronome Therapeutics

Unknown

Safety Study of Oral Vinorelbine in Subjects With Non-Hematologic Malignancies

Nonhematologic Malignancies

United States
TransThera Sciences (Nanjing), Inc.

Recruiting

A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

B-Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/22 Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
AstraZeneca

Active, not recruiting

An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Japan
AstraZeneca

Active, not recruiting

Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Romania, Moldova, Republic of
Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 in Adult Patients With Advanced Malignancies

Cancer, Advanced Malignancies

Canada, United States
Incyte Corporation

Completed

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

B-Cell Malignancies

United States
BeiGene

Completed

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

B-cell Malignancies

United States, Korea, Republic of, Australia, New Zealand, United Kingdom, Italy
Novartis Pharmaceuticals

Completed

Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Netherlands
Millennium Pharmaceuticals, Inc.

Completed

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

Advanced Nonhematologic Malignancies

United States, Spain, France, United Kingdom
Millennium Pharmaceuticals, Inc.

Completed

A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies

Advanced Nonhematologic Malignancies

United States, Spain, United Kingdom
First Affiliated Hospital Xi'an Jiaotong University
Eureka Therapeutics Inc.

Unknown

Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies

B-Cell Malignancies
Samyang Biopharmaceuticals Corporation

Completed

A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies

Advanced Solid Malignancies

Korea, Republic of
Washington University School of Medicine

Completed

Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies

Resistant Solid Malignancies

United States
Millennium Pharmaceuticals, Inc.

Completed

Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C

Advanced Gastrointestinal Malignancies

United States
AstraZeneca

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014

Advanced Solid Malignancies

United Kingdom
Geron Corporation

Completed

Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies

Solid Tumor Malignancies

United States
Regeneron Pharmaceuticals
Sanofi

Completed

A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

United States
Millennium Pharmaceuticals, Inc.

Withdrawn

Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies

Advanced Nonhematologic Malignancies

United States
AstraZeneca

Completed

A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

China
Mayo Clinic
GlaxoSmithKline

Completed

Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies

Advanced Solid Malignancies

United States
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd

Not yet recruiting

Phase I Clinical Study of BR105 Injection (BR105-I)

Advanced Malignancies

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies

Advanced Malignancies

China
Gilead Sciences

Recruiting

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies

Solid Malignancies

United States, Israel
Beijing Mabworks Biotech Co., Ltd.

Recruiting

A Clinical Study of MIL93 in Solid Tumors.

Advanced Malignancies

China
BeiGene

Enrolling by invitation

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Advanced Malignancies

China, Taiwan, Turkey, Korea, Republic of
Incyte Corporation

Terminated

The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

Advanced Malignancies

United States, Italy, Denmark, Japan
University Medical Center Groningen

Terminated

Side Effects of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) Directed Therapy (Mabtornib)

Metastatic Malignancies

Netherlands
Canadian Cancer Trials Group
AstraZeneca

Active, not recruiting

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

Solid Malignancies

Canada
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1501 in Patients With Advanced Tumors

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors

Advanced Malignancies

China
Clover Biopharmaceuticals AUS Pty Ltd

Completed

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal Malignancies

Peritoneal Malignancies

Australia
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread

Advanced Malignancies

Japan
R-Pharm

Completed

Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.

Solid Malignancies

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors

Advanced Malignancies

United States
Southwest Hospital, China

Unknown

A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies

Myeloid Malignancies

China
Infinity Pharmaceuticals, Inc.

Terminated

A Phase 1 Dose Escalation Study of IPI-493

Advanced Malignancies

United States
Mirati Therapeutics Inc.

Completed

Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State

Advanced Malignancies

United States
University of Kentucky
Arno Therapeutics

Completed

A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies

Solid Malignancies

United States

3

Subscribe